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To the Editor:

Obesity has been identified as a risk factor for the development of solid tumors and lymphoid malignancies. A body mass index higher than 30 kg/m^2^ has been estimated to cause 20% of all cancers worldwide. Obese patients also have a higher incidence of non‐Hodgkin lymphomas than patients with normal weight. In addition, obesity is linked to inferior outcomes in established cancer diagnoses, but this excess mortality may be caused in part by higher rates of cardiovascular comorbidities.[1](#cam41980-bib-0001){ref-type="ref"}

There are conflicting results regarding the prognostic role of higher BMI during treatment for aggressive lymphoma and indolent lymphoma. A negative effect of higher body weight is thought to be partly explained by higher rituximab clearance, with an additional role of sex.[2](#cam41980-bib-0002){ref-type="ref"}, [3](#cam41980-bib-0003){ref-type="ref"} Obesity has also been investigated as a risk factor for the development of chronic lymphocytic leukemia (CLL), with conflicting results to date. Nevertheless, the prognostic role of obesity during modern treatment of CLL has not yet been explored. Therefore, we performed an exploratory analysis to define the role of obesity in patients treated in the prospective phase III CLL‐8 trial.

After a rituximab‐containing induction treatment, 263 patients were randomized to either standard observation after treatment or rituximab maintenance for 2 years, as previously described. At a median observation time of 33.4 months, the HR (hazard ratio) for PFS as the primary endpoint of the trial was significantly in favor of rituximab maintenance (HR: 0.5, *P *= 0.0007), as previously reported.[4](#cam41980-bib-0004){ref-type="ref"}

The median BMI for the entire cohort was 26.9, ranging from 17.1 to 40.1. There was no difference regarding the median BMI between the two treatment groups (26.8 and 27.1, respectively). Obesity, defined as a BMI above 30, was diagnosed at study entry in 22.1% of all patients. There were no differences with respect to line of therapy, median age or distribution of gender in obese and non‐obese patients; however, there was a trend toward more high‐risk cytogenetics (del11q or del17p) in non‐obese patients (35.1% vs 20%, *P *= 0.05; for details, see Table [1](#cam41980-tbl-0001){ref-type="table"}A). Despite this fact, obese patients had a lower rate of CR to the last chemoimmunotherapy (43.1% vs 60.0%, *P *= 0.018) and of MRD negativity in the bone marrow (19.6% vs 35.8%, *P *= 0.02) at study entry compared with non‐obese patients in either cohort (Table [1](#cam41980-tbl-0001){ref-type="table"}B).

###### 

Patient characteristics and remission status of patients treated with chemoimmunotherapy (A) and Cox regression analysis of prognostic factors (B)

  A                               Overall (n = 263)   non‐obese (n = 205)   Obese (n = 58)      *P*‐value
  ------------------------------- ------------------- --------------------- ------------------- -------------------------------------------------
  Mean age, years (range, ± SD)   62.9 (35‐85, 9.5)   62.9 (35‐85, 9.7)     62.9 (41‐79, 8.8)   *0.97* [A](#cam41980-note-0002){ref-type="fn"}
  Sex                                                                                           
  Male (%)                        71.1                70.7                  72.4                *0.80* [B](#cam41980-note-0002){ref-type="fn"}
  Female (%)                      28.9                29.3                  27.6                
  Line of treatment                                                                             
  First‐line treatment (%)        79.8                81.5                  74.1                *0.21* [B](#cam41980-note-0002){ref-type="fn"}
  Second‐line treatment (%)       20.2                18.5                  25.9                
  Last induction treatment                                                                      
  FCR (%)                         73.4                73.7                  72.4                *0.85* [B](#cam41980-note-0002){ref-type="fn"}
  Others (%)                      26.6                26.3                  27.6                
  Cytogenetic: del11q or del17p                                                                 
  Yes (%)                         31.9                35.1                  20.0                *0.05* [B](#cam41980-note-0002){ref-type="fn"}
  No (%)                          68.1                64.9                  80.0                
  *Available (*n*/total)*         *213/263*           *168/205*             *45/58*             
  MRD Peripheral blood                                                                          
  Positive (%)                    44.2                42                    51.9                *0.20* [B](#cam41980-note-0002){ref-type="fn"}
  Negative (%)                    55.8                58                    48.1                
  *Available (*n*/total)*         *242/263*           *188/205*             *54/58*             
  MRD Bone marrow                                                                               
  Positive (%)                    44.2                64.2                  80.4                *0.04* [B](#cam41980-note-0002){ref-type="fn"}
  Negative (%)                    55.8                35.8                  19.6                0.02
  *Available (*n*/total)*         *227/263*           *176/205*             *51/58*             
  Response to last induction                                                                    
  CR/CRi (%)                      56.3                60                    43.1                *0.018* [B](#cam41980-note-0002){ref-type="fn"}
  PR (%)                          43.7                40                    56.9                

  B                            Univariate   Multivariate                                  
  ---------------------------- ------------ -------------- ----------- ------ ----------- -----------
  Type of treatment                                                                       
  First line vs second line    0.40         0.26‐0.62      *\<0.001*   0.40   0.24‐0.66   *\<0.001*
  Response to last induction                                                              
  CR/CRi vs PR                 0.44         0.30‐0.66      *\<0.001*   0.45   0.28‐0.73   *0.001*
  Treatment                                                                               
  Maintenance vs observation   0.58         0.39‐0.87      *0.008*     0.46   0.28‐0.74   *0.002*
  Cytogenetics                                                                            
  del17p or del11q yes vs no   0.62         0.40‐0.95      *0.032*     0.66   0.41‐1.06   *0.09*
  Peripheral blood                                                                        
  MRD neg vs pos               0.24         0.16‐0.38      *\<0.001*   0.54   0.32‐0.92   *0.024*
  Bone marrow                                                                             
  MRD neg vs pos               0.12         0.05‐0.25      *\<0.001*   0.26   0.11‐0.61   *0.02*
  Body mass index                                                                         
  BMI\<30 vs BMI\>30           0.63         0.41‐0.97      *0.038*     0.57   0.35‐0.95   *0.033*

[A](#cam41980-note-0002){ref-type="fn"}Mann‐Whitney‐U test, [B](#cam41980-note-0002){ref-type="fn"}Pearson Chi‐Square.

BMI, body mass index; CI, confidence interval; CR, Complete remission; CRi, complete response with incomplete marrow recovery; FCR, fludarabin, cyclophosphamide and rituximab; HR, hazard ratio; MRD, minimal residual disease; PR, partial response; SD: standard deviation.

Italic values indicate the number of available/total patients included into the analysis.
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Consequently, obese patients in the observational arm had inferior clinical outcomes compared to non‐obese patients (median PFS 23.6 vs 38.4 months, HR: 0.55, CI: 0.31‐0.97, *P *= 0.042; Figure [1](#cam41980-fig-0001){ref-type="fig"}).

![Progression‐free survival in the ITT population according to treatment and BMI. The median progression‐free survival was not influenced by obesity in patients treated with rituximab maintenance (median PFS 35.5 months vs not reached, HR: 0.75, CI: 0.38‐1.47, *P *= 0.41). In patients randomized to observation, obesity was associated with a worse median progression‐free survival (median PFS 23.6 vs 38.4 months, HR: 0.55, CI: 0.31‐0.97, *P *= 0.042)](CAM4-8-1401-g001){#cam41980-fig-0001}

Higher body weight is associated with a faster clearance of rituximab in patients with DLBCL.[3](#cam41980-bib-0003){ref-type="ref"} This may explain in part why male patients with DLBCL have an inferior prognosis with rituximab‐based polychemotherapy and may have the most benefit from more intensive rituximab regimens.[5](#cam41980-bib-0005){ref-type="ref"}, [6](#cam41980-bib-0006){ref-type="ref"} Rituximab is essential for achieving deep remissions in CLL, as shown in a randomized clinical trial where the incorporation of rituximab in the induction treatment increased the MRD negativity rate from 28% to 44%.[7](#cam41980-bib-0007){ref-type="ref"} Thus, inferior pharmacodynamics of rituximab in obese CLL patients may lead to inferior outcomes in obese patients treated with chemoimmunotherapy initially.

Considering the randomized design of our study, we were able to test whether rituximab maintenance treatment after chemoimmunotherapy was able to overcome this detrimental effect. When comparing the baseline characteristics between both arms and between obese *versus* non‐obese patients, we found no significant differences (data not shown). We did not observe a negative effect of obesity in patients randomized to rituximab maintenance strategy (median PFS 35.5 months vs not reached, HR: 0.75, CI: 0.38‐1.47, *P *= 0.41; Figure [1](#cam41980-fig-0001){ref-type="fig"}), which suggests that prolonged treatment may overcome the negative effect of obesity in the observational cohort. Consistent with this result, the benefit of rituximab maintenance was more clinically pronounced for the median PFS in obese patients (35.5 vs 23.6 months, HR: 0.46, CI: 0.22‐0.97, *P *= 0.041) compared to non‐obese patients (not reached vs 38.4 months, HR: 0.61, CI: 0.38‐0.96, *P *= 0.032), while remaining significant in both groups.

To assess the independent prognostic relevance of obesity as new risk factor it was added in a multivariate testing to risk factors, which had already been tested in the same data set of the Austrian CLL‐8 trial[4](#cam41980-bib-0004){ref-type="ref"} (see also Table [1](#cam41980-tbl-0001){ref-type="table"}B). This added obesity as a new independent prognostic factor (HR: 0.57; CI: 0.35‐0.95, *P *= 0.033) to the MRD status of peripheral blood (HR: 0.54; CI: 0.32‐0.92, *P *= 0.024) and bone marrow (HR: 0.26; CI: 0.11‐0.61, *P *= 0.002), response to induction treatment (HR: 0.45; CI: 0.28‐0.73, *P *= 0.001), line of induction treatment (HR: 0.40; CI: 0.24‐0.66, *P *\< 0.001) and treatment group (HR: 0.46; CI: 0.28‐0.74, *P *= 0.002). As previously reported and discussed, cytogenetic status, including del17p and del11q, had no significant negative prognostic role in multivariate testing (*P *= 0.09).[4](#cam41980-bib-0004){ref-type="ref"}

To the best of our knowledge, this is the first report showing the negative prognostic role of obesity in CLL patients treated with chemoimmunotherapy. While the role of obesity for the development of CLL remains unclear, we show that obese patients treated with state‐of‐the‐art treatment regimens incorporating rituximab achieved a lower rate CR and MRD negative remissions, which resulted in a lower PFS.

Different pharmacokinetics of rituximab in patients with a higher body mass index may play a role, as suggested by previous results in lymphoma patients with higher body mass indexes.[2](#cam41980-bib-0002){ref-type="ref"}, [3](#cam41980-bib-0003){ref-type="ref"} Other reasons for the inferior outcome in obese patients may be related to the lower levels of vitamin D found to be associated with obesity,[8](#cam41980-bib-0008){ref-type="ref"} or it may be a result of the decreased efficacy of antibody‐mediated cellular cytotoxicity. Regardless of mechanism, rituximab maintenance was able to overcome this negative effect of obesity and provide the same outcomes in obese and non‐obese CLL patients, which suggests that increased rituximab exposure may be especially important for obese populations. This finding may be very relevant in populations with increasing BMI, such as western societies, and it should be confirmed in other trials.
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